Home Sectors Healthcare Latest Change: Pfizer (NYSE: PFE)

Latest Change: Pfizer (NYSE: PFE)


Pfizer is in the drug manufacturers industry and is in the healthcare sector. The company CEO is Albert Bourla. Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

Previous Intraday Trading Performance:

The PFE stock showed a previous change of 0.29% with an open at 41.49 and a close of 41.59. It reached an intraday high of 41.71 and a low of 41.28.

SeekingAlpha:  Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved


The stock has a market cap of $231.2b with 5.6b shares outstanding, of which the float is 5.5b shares. Trading volume reached 22,843,102 shares compared to its average volume of 23,527,326 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Pfizer shares returned 2.29% and in the past 30 trading days it returned -2.74%. Over three months, it changed -0.57%. In one year it has changed 20.15% and within that year its 52-week high was 46.47 and its 52-week low was 35.32. PFE stock is 17.75% above its 52 Week Low.

Our calculations show a 200 day moving average of 41.78 and a 50 day moving average of 41.13. Currently PFE stock is trading -0.45% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.

SeekingAlpha:  Pfizer: A 3.5% Yield, But Lyrica’s Patent Loss Keeps Me From Buying


The last annual fiscal EPS for the company was reported at 1.88 that ended on 31st of December 2018, which according to the previous close, that is a PE of 22.12. Based on 3 analyst estimates, the consensus EPS for the next quarter is 0.78. The TTM EPS is 3.00, which comes to a TTM PE of 13.86. Historically, the PE high was 33.70 and the PE low was 8.70. If the stock reached its PE low, that would represent a price of 26.11, which is a decrease of -37.23%.

The dividend per share is currently 1.44, which is a dividend yield of 3.46%. Also, the payout ratio is 48.00%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 89.75, which means it is possibly undervalued and has a margin of safety of 53.66%

Indicators to Watch:

Short-interest was 65,040,585, which was 1.17% of shares outstanding. The short-interest ratio or days-to-cover ratio was 3.16. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 0.69

SeekingAlpha:  Pfizer: A 3.5% Yield, But Lyrica’s Patent Loss Keeps Me From Buying

Fundamental Indicators:

Based on last reported financials, the company’s return on assets is 7.52%, profit margin is 21.60%, price-to-sales is 4.28 and price-to-book is 3.92.

Company Scores:

All scores are out of six:
 3  :Valuation Score
 2  :Past Performance Score
 3  :Financial Strength Score
 2  :Future Growth Score
 5  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.